Kymera Therapeutics, Inc. financial data

Symbol
KYMR on Nasdaq
Location
500 North Beacon Street, 4 Th Floor, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 822 % +19.1%
Debt-to-equity 16.5 % -43.2%
Return On Equity -31.6 % -9.45%
Return On Assets -27.1 % -21.2%
Operating Margin -698 % -233%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.5M shares +15.8%
Common Stock, Shares, Outstanding 70.6M shares +14.6%
Entity Public Float 1.15B USD +13.2%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 80.4M shares +10.1%
Weighted Average Number of Shares Outstanding, Diluted 80.4M shares +10.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 44.7M USD -49.5%
Cost of Revenue 11.5M USD -55.3%
Research and Development Expense 291M USD +39.1%
General and Administrative Expense 65.7M USD +9.33%
Operating Income (Loss) -312M USD -68.1%
Income Tax Expense (Benefit) 200K USD
Net Income (Loss) Attributable to Parent -275M USD -74.5%
Earnings Per Share, Basic -3 USD/shares -43.8%
Earnings Per Share, Diluted -3 USD/shares -43.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 336M USD +397%
Accounts Receivable, after Allowance for Credit Loss, Current 40M USD
Assets, Current 728M USD +38.6%
Property, Plant and Equipment, Net 48.6M USD -6.11%
Operating Lease, Right-of-Use Asset 46M USD -5.46%
Other Assets, Noncurrent 4.68M USD +147%
Assets 1.13B USD +36.9%
Accounts Payable, Current 5.78M USD -11.2%
Accrued Liabilities, Current 28M USD +17.6%
Contract with Customer, Liability, Current 40M USD +108%
Liabilities, Current 87.5M USD +40.9%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 69.8M USD -6.67%
Other Liabilities, Noncurrent 0 USD
Liabilities 160M USD +13.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 279K USD
Retained Earnings (Accumulated Deficit) -897M USD -44.3%
Stockholders' Equity Attributable to Parent 971M USD +41.8%
Liabilities and Equity 1.13B USD +36.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -79.2M USD -99.9%
Net Cash Provided by (Used in) Financing Activities 258K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 48.6M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 70.6M shares +14.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30.3M USD -84.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 77K USD +57.1%
Deferred Tax Assets, Valuation Allowance 236M USD +45.5%
Deferred Tax Assets, Gross 260M USD +41.1%
Operating Lease, Liability 81.6M USD -5.39%
Depreciation 7.3M USD +40.4%
Payments to Acquire Property, Plant, and Equipment 467K USD -93.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -273M USD -74.7%
Lessee, Operating Lease, Liability, to be Paid 119M USD -9.09%
Property, Plant and Equipment, Gross 68.8M USD +7.11%
Operating Lease, Liability, Current 11.8M USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.4M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 37.3M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.2M USD +3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.6M USD +3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.05M USD +40.2%
Deferred Tax Assets, Net of Valuation Allowance 23.6M USD +8.54%
Share-based Payment Arrangement, Expense 58.4M USD +19.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares